The State of the Microbiome

Table of Contents

1 Study Design

• 1.1 Background, Objectives, and Design
• 1.2 Respondent Mix - Geography
• 1.3 Respondent Mix - Seniority Level and Company Size

2 Executive Summary

• 2.1 Executive Summary

3 Microbiome Investment

• 3.1 Gastroenterology and Infectious Disease Mark the Most Active Therapy Areas
• 3.2 Infectious Disease and Gastroenterology Most Highly Invested Therapy Areas
• 3.3 A Closer Look at the Microbiome Pipeline
• 3.4 Microbiome Pipeline Targeting Gastrointestinal Indications and Infectious Diseases
• 3.5 A Closer Look at the Microbiome Pipeline Targeting Gastrointestinal Indications
• 3.6 A Closer Look at the Microbiome Pipeline Targeting Infectious Diseases

4 Challenges with Developing Microbiome Therapeutics

• 4.1 Identifying the Mechanism of Action Seen as a Major Challenge
• 4.2 Identifying the Mechanism of Action Is Seen as the Most Challenging Factor
• 4.3 A Closer Look by Seniority Level

5 Challenges with Launching Microbiome Therapeutics

• 5.1 Manufacturing Identified as a Major Challenge
• 5.2 Manufacturing Identified As the Most Challenging Factor
• 5.3 A Closer Look by Seniority Level

6 Challenges with Manufacturing Microbiome Therapeutics

• 6.1 Dose Formulation Is a Major Challenge

7 Key Findings and Recommendations

• 7.1 Summary of Key Findings
• 7.2 Recommendations

8 Appendix

• 8.1 Related Reports
• 8.2 Abbreviations
• 8.3 Primary Research
• 8.4 About the Authors
• 8.5 About Thematic Research
• 8.6 About GlobalData
• 8.7 Contact Us